Decoy Therapeutics Inc. carries no debt; cash flow comfortably covers obligations.

Decoy Therapeutics Inc.'s free cash flow has decreased 6.67% from $-4.53M last year to $-4.83M, signaling decreasing performance

Decoy Therapeutics Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Decoy Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.15 last year to 0.00 today, signaling strengthened financials

Decoy Therapeutics Inc. has a net cash position, so leverage is healthy.

Decoy Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Decoy Therapeutics Inc. has insufficient data to evaluate this check.

Decoy Therapeutics Inc.'s short-term assets of $10.99M exceed its short-term liabilities of $5.17M

Decoy Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Decoy Therapeutics Inc.'s return on equity of -395.42%, is lower than 15.00%, indicating bad performance

Decoy Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Decoy Therapeutics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Decoy Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Decoy Therapeutics Inc. has negative free cash flow, indicating cash burn

Decoy Therapeutics Inc.'s yearly earnings has decreased 124.52% since last year from $-5.58M to $-12.52M, signaling decreasing performance

Decoy Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -339.89% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Decoy Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Decoy Therapeutics Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Decoy Therapeutics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Decoy Therapeutics Inc. has insufficient data to evaluate this check.

Decoy Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Decoy Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Decoy Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Decoy Therapeutics Inc. has insufficient data to evaluate this check.

Decoy Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Decoy Therapeutics Inc. has a price-to-book ratio of 0.53x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Decoy Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue